Does liposomal doxorubicin-based chemotherapy improve ORR and reduce cardiotoxicity in patients with advanced breast cancer?
Liposomal doxorubicin-based chemotherapy improves objective response rates and reduces cardiotoxicity in advanced breast cancer.
The results of this meta-analysis suggest that liposomal doxorubicin-based chemotherapy is associated with a significant improvement in the ORR and a significant reduction in the risk of cardiotoxicity.
Xing et al. (2015) studied this question.